The size of the global cartilage regeneration market is estimated to value USD 1860.00 million by 2029 from USD 934.94 million in 2024, growing at a CAGR of 14.2% during the forecast period.
The primary function of cartilage is to connect bones. It does so by its elasticity to bend a bit but, at the same time, resisting stretching. It is found in many body parts, such as joints, ribcages, nose, ear, throat, and backbones. However, the amplest type of cartilage found in the human body is the hyaline cartilage, which is seen as supportive tissue in the ears, nose, and throat (trachea, smaller respiratory tubes, larynx). Cartilage tissue is vital because of the flexibility and stability of movement it provides.
In addition, over the forecast period, an increase in the frequency of traffic accidents and sports-related injuries resulting in bone and joint injuries is expected to fuel demand for cartilage regeneration products. The growing number of cartilage regeneration products being developed reflects the sector's growing interest and technological advancements. Basic research advances in cartilage repair led to improved therapeutic therapies, but their effectiveness depends on their capacity to simplify surgical procedures and increase tissue regeneration.
The global market for cartilage regeneration is further projected to be driven by the growing prevalence of bone, stem cell-based tissue engineering, and joint diseases and technical improvements in cartilage regeneration in the coming years. In addition, the market is expected to increase in the next few years as the elderly population grows and the incidence of sports injuries rises. Furthermore, during the forecasted period, the rising incidence of diabetes is expected to boost the cartilage regeneration market.
The high cost of cartilage repair operations is estimated to restrict the growth of the global cartilage regeneration market. There are a lot of restrictions and obstacles that might stymie cartilage regeneration market expansion. The cartilage regeneration market will likely be challenged by a lack of cartilage-based stem cell products. A few constraints are expected to include unfavorable reimbursement scenarios and increasing therapeutic costs.
COVID-19 is an unprecedented worldwide public health crisis that has impacted nearly every business. The long-term repercussions are expected to influence industry growth throughout the forecast period. During the first half of the forecast period, the COVID-19 outbreak will influence the cartilage regeneration market. The cartilage regeneration market is anticipated to drop during the first phase of the forecasted period due to countrywide lockdowns, denied wound care services, and canceled or postponed elective procedures. In addition, patients cannot access hospitals, outpatient clinics, or clinics due to the lockdowns. During the forecasted period, this temporary denial of wound care services, cancer care surgeries/therapies, and other healthcare services are likely to hinder the growth of the cartilage regeneration market. However, during the second phase of the pandemic, it regains its growth and is likely to continue in the future.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Type of treatment, application, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis; Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
Zimmer Biomet Holdings, Inc. (U.S.), Vericel Corporation (U.S.), Smith & Nephew plc (U.K.), Osiris Therapeutics, Inc. (U.S.), and Arthrex Inc. (U.S.). |
Based on the type of treatment, the cell-based approach segment of the global cartilage regeneration market held the highest share of the treatment modality segment. Technology developments in stem cell-based treatments for cartilage repair and chondrocyte implantation products are responsible for a substantial part of this market. As a result, the cell-based category led the market, and it is anticipated to increase at a healthy rate over the next several years. It is also expected to expand due to the rising demand for autologous chondrocyte transplants for surgical treatment of damaged articular cartilage (chondral and osteochondral lesions).
In the Non-Cell-Based Approaches segment, Tissue scaffolds and cell-free composites are two types of non-cell-based materials. The tissue scaffold segment has the largest share after the cell-based approach segment. When transplanted into the knees and other joints, tissue scaffolds can encourage cartilage and bone development; thus, they are utilized more frequently than cell-free composites.
Based on the application, because of the growing incidences of physical trauma throughout the world, which can induce osteochondral and chondral lesions in patients, the Hyaline cartilage regeneration segment is expected to dominate this market over the forecast period. Furthermore, due to the high sensitivity of hyaline cartilage to damage in the event of cartilage-related accidents, the hyaline segment is likewise predicted to develop at the quickest rate throughout the projection period. Furthermore increased sports-related injuries leadeads to articular cartilage abnormalities in the knee and other joints, which is expected to promote sector growth.
Geographically, North America leads the global market, accounting for the significant global market share and expanding with the highest CAGR during the forecast period. North America’s lead is warranted by the presence of a high number of registered patients and increasing the use of cartilage repair or regeneration to treat sports injuries and other accidents. Due to the increased incidence of bone and joint diseases, an increase in the number of accidents and injuries, and the expanding population in the area, North America is anticipated to lead the cartilage regeneration market over the forecast period. Furthermore, rising physician and patient awareness of newly developed treatment methods and technologies, as well as significant government investments in the technologies and therapies used in Cartilage Repair/Regeneration, are all contributing to the market's rise in North America. Furthermore, because of the rising incidence of musculoskeletal disorders, target populations, and changing lifestyles of persons in the United States and Canada, North America represented the largest market in 2023.
The European market comes in second in terms of market share due to rising awareness about blood-related disorders and the swift availability of treatment in plasma fractionation.
However, Asia-Pacific is expected to catch up fast during the forecast period because of a vast population base once the costs of cartilage regeneration come down with growth in R&D and technology. Furthermore, the cartilage regeneration market in the Asia Pacific is expected to expand at the fastest CAGR during the forecast period, owing to the growing elderly population and the resulting rise in the prevalence of different diseases and injuries. In addition, recent advancements in tissue engineering and stem cell treatment are expected to boost market growth even further.
Over the forecast period, the cartilage repair market is likely to be governed by the growing incidence of diabetes and obesity worldwide. Diabetes leads to a greater loss of cartilage. Furthermore, throughout the forecast period, global growth in the obese (overweight) population, primarily in Latin America and the Middle East Africa region, is projected to boost demand for cartilage repair products.
A few of the noteworthy companies operating in the global cartilage regeneration market profiled in this report are Zimmer Biomet Holdings, Inc. (U.S.), Vericel Corporation (U.S.), Smith & Nephew plc (U.K.), Osiris Therapeutics, Inc. (U.S.), and Arthrex Inc. (U.S.).
By Type of Treatment
By Application
By Region
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region